→ Having helped turn “the vision of computational-based drug discovery into reality” at Nimbus Therapeutics, founding CSO Rosana Kapeller has decided it’s time to take on an executive leadership role elsewhere. During her eight-year tenure, the Cambridge, MA-based biotech has built up a pipeline spanning metabolic, autoimmune and immuno-oncology programs. That has attracted big partners and big bucks from Gilead, Genentech and Celgene. Before joining Nimbus, Kapeller co-founded Aileron Therapeutics. “Rosana is a top-notch scientist who is uniformly admired by the team at Nimbus and our wide array of corporate and academic partners,” Nimbus CEO Don Nicholson said in a farewell statement. “She has helped assemble a talented, high caliber drug discovery organization which is larger and more capable than at any time in our history, and the deep experience and talent of our leadership team has enabled a seamless transition.”
→ AI startup BioXcel had to settle for a $60 million raise from its IPO. The biotech sold 5.4 million shares at $11 each. Underwriters have a 30-day option to purchase up to an additional 818,181 shares at that price.
→ Cytox and its partners at Cardiff University has been granted £800,000 ($1.3 million) by Innovate UK to further evaluate the genetic test they have developed for prodromal Alzheimer’s disease, .
With contribution from John Carroll.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription